GERN

Geron Corporation

GERN, USA

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

https://www.geron.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GERN
stock
GERN

Geron (NASDAQ:GERN) Trading Up 8.2% - What's Next? MarketBeat

Read more →
GERN
stock
GERN

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025) ts2.tech

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3.3333

Analyst Picks

Strong Buy

4

Buy

2

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.65

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-7.41 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.25 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-28.93 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 82.64% of the total shares of Geron Corporation

1.

RA Capital Management, LLC

(9.4636%)

since

2025/06/30

2.

BlackRock Inc

(7.8405%)

since

2025/06/30

3.

Deep Track Capital, LP

(6.7396%)

since

2025/06/30

4.

Vanguard Group Inc

(5.582%)

since

2025/06/30

5.

Vivo Capital, LLC

(4.2672%)

since

2025/06/30

6.

Vestal Point Capital LP

(3.7264%)

since

2025/06/30

7.

State Street Corp

(3.704%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.0146%)

since

2025/07/31

9.

Soleus Capital Management, L.P.

(2.5297%)

since

2025/06/30

10.

iShares Russell 2000 ETF

(2.2657%)

since

2025/08/31

11.

ClearBridge Advisors, LLC

(2.2533%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.2181%)

since

2025/06/30

13.

BioPharma Credit Ord

(2.2138%)

since

2024/12/31

14.

Morgan Stanley - Brokerage Accounts

(2.0839%)

since

2025/06/30

15.

Citadel Advisors Llc

(1.8865%)

since

2025/06/30

16.

UBS Group AG

(1.8409%)

since

2025/06/30

17.

SPDR® S&P Biotech ETF

(1.5821%)

since

2025/08/31

18.

Goldman Sachs Group Inc

(1.5385%)

since

2025/06/30

19.

Point72 Asset Management, L.P.

(1.5056%)

since

2025/06/30

20.

Fidelity Select Biotechnology

(1.4228%)

since

2025/07/31

21.

Vanguard Explorer Inv

(1.3984%)

since

2025/06/30

22.

Woodline Partners LP

(1.2536%)

since

2025/06/30

23.

Eversept Partners, LLC

(1.1473%)

since

2025/06/30

24.

Segall Bryant & Hamill

(1.1273%)

since

2025/06/30

25.

Aberdeen Group PLC

(1.0949%)

since

2025/06/30

26.

StemPoint Capital LP

(1.0422%)

since

2025/06/30

27.

Fidelity Small Cap Index

(0.9558%)

since

2025/06/30

28.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9556%)

since

2025/07/31

29.

iShares Russell 2000 Growth ETF

(0.8271%)

since

2025/08/31

30.

ClearBridge Small Cap Growth A

(0.5905%)

since

2025/07/31

31.

ClearBridge Small Cap Growth

(0.5905%)

since

2025/07/31

32.

abrdn Healthcare Investors

(0.5689%)

since

2025/08/31

33.

iShares Biotechnology ETF

(0.5661%)

since

2025/08/31

34.

Xtrackers MSCI World Swap ETF 1C

(0.5224%)

since

2025/07/31

35.

Fidelity Extended Market Index

(0.4748%)

since

2025/07/31

36.

Vanguard Russell 2000 ETF

(0.4543%)

since

2025/07/31

37.

Schwab US Small-Cap ETFâ„¢

(0.4078%)

since

2025/08/30

38.

EdRF Healthcare A EUR

(0.3652%)

since

2025/07/31

39.

State St Russell Sm Cap® Indx SL Cl I

(0.3232%)

since

2025/08/31

40.

abrdn Life Sciences Investors

(0.2982%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.03

EPS Estimate

-0.0256

EPS Difference

-0.0044

Surprise Percent

-17.1875%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.